Patient eligibility
hypertension/diabetes mellitus, interstitial pneumonia, cancer, adenosquamous carcinoma, squamous cell lung cancer, watery diarrhea, Tumors, pericardial effusion, infection
RECURRENCE, CARDIOVASCULAR DISEASE, INTESTINAL OBSTRUCTION, INTERSTITIAL PNEUMONIA, DRUG HYPERSENSITIVITY, CANCER, DISEASE, ADENOSQUAMOUS CARCINOMA, SQUAMOUS CELL LUNG CANCER, BRAIN METASTASES, TUMORS, PERICARDIAL EFFUSION, INFECTION, INTESTINAL PARALYSIS, COMPLICATIONS
The main eligibility criteria were: (1) histologically or cytologically confirmed squamous cell lung cancer with a predominant squamous component, or adenosquamous carcinoma with a predominant squamous component; (2) unresectable stage III disease without an indication for curative irradiation, stage IV disease, or postoperative recurrence; (3) age >20 years; (4) measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1);The main exclusion criteria were: (1) evidence of interstitial pneumonia on chest radiography; (2) a history of drug hypersensitivity; (3) active double cancer; (4) pleural, peritoneal, and pericardial effusion requiring drainage; (5) serious complications (symptomatic cardiovascular disease, uncontrolled hypertension/diabetes mellitus, and active infection); (6) symptomatic brain metastases; (7) previously treated with S‐1, uracil‐tegafur, and CPT‐11; (8) watery diarrhea; (9) intestinal paralysis or intestinal obstruction; (10) treated with flucytosine; (11) treated with atazanavir sulfate; and (12) women who were pregnant, intending to become pregnant, or breast‐feeding.